Polymyalgia Rheumatica Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment
Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older. This study evaluates how safe and effective ABBV-154 is in participants with glucocorticoid-dependent PMR. Adverse events and change in disease activity will be assessed. ABBV-154 is an investigational drug being evaluated for the treatment of PMR. Participants will be randomized into 1 of 4 treatment groups or arms, each arm receiving a different treatment. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 participants, of at least 50 years of age, with PMR will be enrolled in the study at approximately 95 sites worldwide. The study is compromised of a 52 week double-blind, placebo-controlled period and a follow-up visit 70 days after the last dose of the study drug. All participants will receive a glucocorticoid taper along with the assigned dose of ABBV-154 or placebo, subcutaneously (SC) every other week (eow). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
| Terminated |
NCT03600818 -
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT00836810 -
Timed Release Tablet Prednisone in Polymyalgia Rheumatica
|
Phase 2/Phase 3 | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Completed |
NCT03263715 -
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)
|
Phase 3 | |
| Recruiting |
NCT05935709 -
DANIsh VASculitis Database (DANIVAS)
|
||
| Not yet recruiting |
NCT02985424 -
Polymyalgia Rheumatica and Giant Cell Arteritis
|
N/A | |
| Completed |
NCT00138983 -
Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.
|
Phase 3 | |
| Recruiting |
NCT06130540 -
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
|
Phase 1 | |
| Recruiting |
NCT05767034 -
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
|
Phase 3 | |
| Terminated |
NCT01821040 -
A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR
|
Phase 3 | |
| Recruiting |
NCT00982332 -
Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica
|
N/A | |
| Recruiting |
NCT05312944 -
Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
|
||
| Recruiting |
NCT04664465 -
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
|
||
| Withdrawn |
NCT02899026 -
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
|
Phase 3 | |
| Not yet recruiting |
NCT06281236 -
A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)
|
Phase 1 | |
| Recruiting |
NCT03576794 -
Treatment With Leflunomide in Patients With Polymyalgia Rheumatica
|
Phase 3 | |
| Completed |
NCT05681676 -
Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
|
||
| Recruiting |
NCT05435781 -
Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency
|
Phase 4 | |
| Terminated |
NCT03656627 -
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
|
Phase 1 |